Apis Assay Technologies Ltd.

Apis Assay Technologies Ltd. is focused on developing molecular diagnostic assays and bioinformatics solutions, particularly for oncology and pharmacogenomics, enhancing personalized medicine through innovative technology. Apis Assay Technologies Ltd. was founded in 2018 and specializes in molecular diagnostics.

The company was established by Joachim Schorr, with Ian Kavanagh serving as the CEO. Headquartered in London, UK, the company has not undergone any significant changes in business strategy since its inception. Apis Assay Technologies Ltd specializes in the development of innovative molecular diagnostic assays and bioinformatics solutions, primarily targeting oncology and pharmacogenomics markets. Their core offerings include a range of RT-qPCR and dPCR kits designed for the detection of specific mutations and biomarkers associated with cancer.

Notable products include the Breast Cancer Subtyping Kit, which detects established biomarkers such as HER2, ER, PR, and Ki67, alongside novel proliferative markers. Their ESR1 qPCR and dPCR Kits enable precise identification of 11 critical mutations in the oestrogen receptor gene, while the PIK3CA qPCR Kit focuses on the five most prevalent mutations in the PIK3CA gene. The company also offers the DPYD qPCR and HT qPCR Kits for the detection of multiple DPYD variants. These products serve clinical laboratories and research facilities, predominantly in the United Kingdom and Europe, where they support oncologists and healthcare providers in delivering tailored treatment plans based on genetic insights.

Apis Assay Technologies operates on a business-to-business (B2B) model, primarily generating revenue through direct sales of its diagnostic kits to clinical laboratories and healthcare facilities. The company’s revenue structure includes one-time transactions for individual assay kits, which are typically priced to reflect their advanced technology and the critical data they provide for patient management. For example, flagship products like the ESR1 and PIK3CA qPCR Kits are marketed to oncology professionals and diagnostic centers that require precise mutation detection for personalized treatment strategies. In addition to the sale of diagnostic products, the company may engage in partnerships with biotech and pharmaceutical companies, further enhancing its revenue stream through collaborative projects involving assay development and bioinformatics services.